Verano Holdings (VRNO) Amortization of Deferred Charges (2021 - 2026)
Verano Holdings (VRNO) posted quarterly Amortization of Deferred Charges of $3.0 million for Q1 2026, up 1.52% year-over-year from $3.0 million in Q1 2025, and little changed quarter-over-quarter from $3.0 million in Q4 2025.
Verano Holdings (VRNO) Amortization of Deferred Charges (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has reported Amortization of Deferred Charges for 6 consecutive years, with $3.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortization of Deferred Charges rose 1.52% year-over-year to $3.0 million; the TTM figure through Mar 2026 stood at $12.0 million (up 7.2% YoY), while the FY2025 annual figure was $12.0 million, up 7.1% from the prior year.
- Amortization of Deferred Charges was little changed at $3.0 million in Q1 2026 per VRNO's latest filing, from $3.0 million in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $3.9 million in Q2 2024 and bottomed at $1.5 million in Q1 2022.
- Historically, Amortization of Deferred Charges has averaged $2.7 million across 5 years, with a median of $2.7 million in 2023.
- Annual changes were most pronounced in 2022 — Amortization of Deferred Charges surged 167.88% — and 2024, when it tumbled 34.9%.
- Verano Holdings' Amortization of Deferred Charges stood at $2.5 million in 2022, then advanced by 7.64% to $2.7 million in 2023, then sank by 34.9% to $1.7 million in 2024, then surged by 74.5% to $3.0 million in 2025, then dropped by 0.46% to $3.0 million in 2026.
- Business Quant data shows VRNO's Amortization of Deferred Charges at $3.0 million in Q1 2026, $3.0 million in Q4 2025, and $3.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Verano Holdings | 449.04 Mn | 363.85 Mn | 99.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.09 Mn |
| Jun 30, 2026 | 3.09 Mn |
| Mar 31, 2026 | 3.01 Mn |
| Mar 31, 2026 | 3.01 Mn |
| Dec 31, 2025 | 3.02 Mn |
| Dec 31, 2025 | 3.02 Mn |
| Sep 30, 2025 | 3.00 Mn |
| Sep 30, 2025 | 3.00 Mn |
| Jun 30, 2025 | 3.01 Mn |
| Jun 30, 2025 | 3.01 Mn |
| Mar 31, 2025 | 2.97 Mn |
| Mar 31, 2025 | 2.97 Mn |
| Dec 31, 2024 | 1.73 Mn |
| Dec 31, 2024 | 1.73 Mn |
| Sep 30, 2024 | 2.65 Mn |
| Sep 30, 2024 | 2.65 Mn |
| Jun 30, 2024 | 3.88 Mn |
| Jun 30, 2024 | 3.88 Mn |
| Mar 31, 2024 | 2.93 Mn |
| Mar 31, 2024 | 2.93 Mn |